A speedy and efficient mechanism to challenge improvidently granted patents is essential to the timely provision of generic and biosimilar medicines. The availability of generic and biosimilar medicines saves money and provides greater patient access to critical medicines. See our amicus brief on how the Inter partes review is essential to the limited regulatory objective of eliminating invalid patents.
